2023
The Cooperative Re-Engagement Controlled Trial (CoRECT): Durable Viral Suppression Assessment
O'Shea J, Fanfair R, Williams T, Khalil G, Brady K, DeMaria A, Villanueva M, Randall L, Jenkins H, Altice F, Camp N, Lucas C, Buchelli M, Samandari T, Weidle P. The Cooperative Re-Engagement Controlled Trial (CoRECT): Durable Viral Suppression Assessment. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2023, 93: 134-142. PMID: 36812382, PMCID: PMC10962216, DOI: 10.1097/qai.0000000000003178.Peer-Reviewed Original ResearchConceptsDurable viral suppressionActive public health interventionProportion of PWHPublic health interventionsViral loadCare strategiesHealth interventionsLast viral loadCopies/mLStandard of careRace/ethnicityCare armHIV careViral suppressionAntiretroviral adherenceCD4 categoryExposure categoriesCare individualsPWHCareAge categoriesInterventionTrialsBirth sexRe-Engagement
2021
Use of Pre-exposure Prophylaxis Among People Who Inject Drugs: Exploratory Findings of the Interaction Between Race, Homelessness, and Trust
Zhou X, Altice FL, Chandra D, Didomizio E, Copenhaver MM, Shrestha R. Use of Pre-exposure Prophylaxis Among People Who Inject Drugs: Exploratory Findings of the Interaction Between Race, Homelessness, and Trust. AIDS And Behavior 2021, 25: 3743-3753. PMID: 33751313, DOI: 10.1007/s10461-021-03227-7.Peer-Reviewed Original ResearchConceptsPre-exposure prophylaxisPrEP useProvider trustPatient-level factorsOpioid-dependent patientsLogistic regression analysisNon-homeless participantsHomeless participantsRace/ethnicityEligibility criteriaCross-sectional dataPrEPProphylaxisMethadoneRegression analysisDrugsExploratory findingsParticipantsPotential moderatorsPWIDPatientsSignificant moderator
2020
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.Peer-Reviewed Original ResearchConceptsCytokine release syndromeTocilizumab-treated patientsSevere diseaseRelease syndromeTocilizumab treatmentInflammatory biomarkersNonsevere diseaseSoluble IL-2 receptor levelsHigh-sensitivity C-reactive proteinIL-2 receptor levelsConsecutive COVID-19 patientsIL-6 receptor antagonistMechanical ventilation outcomesC-reactive proteinCOVID-19 patientsHigher admission levelsRace/ethnicityMV daysVentilation outcomesAdverse eventsChart reviewClinical responseMedian ageWhite patientsClinical outcomes
2014
Optimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison Gate
Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison Gate. JAMA Internal Medicine 2014, 174: 721-729. PMID: 24687044, PMCID: PMC4074594, DOI: 10.1001/jamainternmed.2014.601.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsCD4 lymphocyte countViral suppressionHIV viral suppressionLymphocyte countObserved therapyRNA levelsBaseline HIV-1 RNA levelsMean HIV-1 RNA levelHuman immunodeficiency virus (HIV) treatmentHuman immunodeficiency virus managementHIV treatment outcomesRetrospective cohort studyAntiretroviral therapy regimensHIV-1 RNAPsychiatric disorder severityLogistic regression modelsCommunity-based resourcesDuration of incarcerationRace/ethnicityART regimenContinuous ARTPrescribed pharmacotherapyAntiretroviral therapyART regimens
2005
Attitudes toward and beliefs about prenatal HIV testing policies and mandatory HIV testing of newborns among drug users.
Fielder O, Altice FL. Attitudes toward and beliefs about prenatal HIV testing policies and mandatory HIV testing of newborns among drug users. AIDS & Public Policy Journal 2005, 20: 74-91. PMID: 17624031.Peer-Reviewed Original ResearchConceptsHIV testingLongitudinal cohort studyMandatory HIV testingPregnant womenDrug usersCohort studyMandatory testingCertain races/ethnicitiesPerinatal HIV testingPrior HIV testingHigh-risk womenHIV testing policiesHealthcare systemActive drug usersMajority of subjectsFocus groupsStructured interviewsRace/ethnicityRespondent-driven samplingHIV statusBaby's healthAdverse outcomesPrenatal careSuboptimal careHealth beliefs